J Biomed Opt. 2011 Apr;16(4):040501. doi: 10.1117/1.3560624.
The identification of breast cancer patients who will ultimately progress to metastatic disease is of significant clinical importance. The quantification and assessment of circulating tumor cells (CTCs) has been proposed as one strategy to monitor treatment effectiveness and disease prognosis. However, CTCs have been an elusive population of cells to study because of their small number and difficulties associated with isolation protocols. In vivo flow cytometry (IVFC) can overcome these limitations and provide insights in the role these cells play during primary and metastatic tumor growth. In this study, we used two-color IVFC to examine, for up to ten weeks following orthotopic implantation, changes in the number of circulating human breast cells expressing GFP and a population of circulating hematopoietic cells with strong autofluorescence. We found that the number of detected CTCs in combination with the number of red autofluorescent cells (650 to 690 nm) during the first seven days following implantation was predictive in development of tumor formation and metastasis eight weeks later. These results suggest that the combined detection of these two cell populations could offer a novel approach in the monitoring and prognosis of breast cancer progression, which in turn could aid significantly in their effective treatment.
确定最终会发展为转移性疾病的乳腺癌患者具有重要的临床意义。定量和评估循环肿瘤细胞(CTC)已被提议作为监测治疗效果和疾病预后的一种策略。然而,由于 CTC 数量较少,且与分离方案相关的困难,它们一直是难以研究的细胞群体。体内流式细胞术(IVFC)可以克服这些限制,并深入了解这些细胞在原发性和转移性肿瘤生长过程中所起的作用。在这项研究中,我们使用双色 IVFC 来检查在原位植入后长达十周内,表达 GFP 的循环人乳腺细胞数量和具有强烈自发荧光的循环造血细胞数量的变化。我们发现,在植入后前七天内检测到的 CTC 数量与红色自发荧光细胞(650 至 690nm)的数量相结合,可预测八周后肿瘤形成和转移的发展。这些结果表明,这两种细胞群体的联合检测可能为监测和预测乳腺癌进展提供一种新方法,从而显著有助于其有效治疗。